TABLE 1.
General characteristics of systematic reviews1
Reviews (n = 150) | |
---|---|
Journal | |
General nutrition journal (journals with only a nutrition focus, e.g., The American Journal of Clinical Nutrition) | 61 (40.7) |
Specialized nutrition journal (journals with a focus on nutrition and a specific disease area, e.g., Nutrition,Metabolism and Cardiovascular Diseases) | 7 (4.7) |
General medical journal (e.g., Lancet) | 28 (18.7) |
Specialized medical journal (e.g., Clinical Breast Cancer) | 54 (36.0) |
Country of primary affiliation of corresponding author | |
North America | 14 (9.3) |
Europe | 43 (28.7) |
Oceania | 13 (8.7) |
Middle East | 28 (18.7) |
Asia | 49 (32.7) |
South America | 3 (0.7) |
Was the review conducted to inform a particular guideline or policy decision or to fulfill the needs of a particular evidence user? | |
Yes | 6 (4.0) |
No | 144 (96.0) |
Funding2 | |
Government support | 56 (37.3) |
Institutional support | 34 (22.7) |
Private not-for-profit foundation | 20 (13.3) |
Food marketing/advocacy organizations | 4 (2.7) |
Food companies | 2 (1.3) |
No funding | 32 (21.3) |
Not reported | 34 (22.7) |
Did the authors declare any conflicts of interest? | |
Yes | 10 (6.7) |
No | 135 (90.0) |
Not reported | 5 (3.3) |
Exposures2 | |
Micronutrient | 27 (18.0) |
Macronutrient | 24 (16.0) |
Bioactive compounds | 15 (10.0) |
Food or beverage | 60 (40.0) |
Food group | 21 (14.0) |
Dietary pattern | 49 (32.7) |
Nonnutritive components of foods/beverages | 25 (18.7) |
Outcomes2 | |
Cardiometabolic morbidity or mortality | 26 (17.3) |
Cancer morbidity or mortality | 54 (36.0) |
Diseases of the digestive system | 10 (6.7) |
All-cause mortality | 9 (6.0) |
Anthropometric measures | 8 (5.3) |
Surrogate outcomes | 17 (11.3) |
Other | 55 (36.7) |
Primary studies, n | 15 [11–23] |
Participants, n | 208,117 [84,951–510,954] |
Values are n (%) or median [IQR].
Each review can be classified in >1 category.